O	0	1	[	[	(	O
O	1	9	Clinical	Clinical	JJ	B-NP
O	10	22	significance	significance	NN	I-NP
O	23	25	of	of	IN	B-PP
O	26	37	interleukin	interleukin	NN	B-NP
O	37	38	-	-	HYPH	B-NP
O	38	39	6	6	CD	I-NP
O	40	41	(	(	(	O
O	41	43	IL	IL	NN	B-NP
O	43	44	-	-	HYPH	O
O	44	45	6	6	CD	B-NP
O	45	46	)	)	)	O
O	47	49	as	as	IN	B-PP
O	50	51	a	a	DT	B-NP
O	52	62	prognostic	prognostic	JJ	I-NP
O	63	69	factor	factor	NN	I-NP
O	70	72	of	of	IN	B-PP
B-Cancer	73	79	cancer	cancer	NN	B-NP
O	80	87	disease	disease	NN	I-NP
O	87	88	]	]	)	O

O	89	100	Interleukin	Interleukin	NN	B-NP
O	100	101	-	-	HYPH	I-NP
O	101	102	6	6	CD	I-NP
O	103	104	(	(	(	O
O	104	106	IL	IL	NN	B-NP
O	106	107	-	-	HYPH	B-NP
O	107	108	6	6	CD	I-NP
O	108	109	)	)	)	O
O	110	112	is	be	VBZ	B-VP
O	113	128	proinflammatory	proinflammatory	JJ	B-NP
O	129	137	cytokine	cytokine	NN	I-NP
O	138	142	that	that	WDT	B-NP
O	143	151	produces	produce	VBZ	B-VP
O	152	167	multifunctional	multifunctional	JJ	B-NP
O	168	175	effects	effect	NNS	I-NP
O	175	176	.	.	.	O

O	177	179	It	It	PRP	B-NP
O	180	182	is	be	VBZ	B-VP
O	183	187	also	also	RB	I-VP
O	188	196	involved	involve	VBN	I-VP
O	197	199	in	in	IN	B-PP
O	200	203	the	the	DT	B-NP
O	204	214	regulation	regulation	NN	I-NP
O	215	217	of	of	IN	B-PP
O	218	224	immune	immune	JJ	B-NP
O	225	234	reactions	reaction	NNS	I-NP
O	234	235	,	,	,	O
O	236	249	hematopoiesis	hematopoiesis	NN	B-NP
O	250	253	and	and	CC	O
O	254	266	inflammatory	inflammatory	JJ	B-NP
O	267	272	state	state	NN	I-NP
O	272	273	.	.	.	O

O	274	285	Interleukin	Interleukin	NN	B-NP
O	285	286	-	-	HYPH	O
O	286	287	6	6	CD	B-NP
O	288	291	has	have	VBZ	B-VP
O	292	296	been	be	VBN	I-VP
O	297	302	shown	show	VBN	I-VP
O	303	305	to	to	TO	I-VP
O	306	308	be	be	VB	I-VP
O	309	319	associated	associate	VBN	I-VP
O	320	324	with	with	IN	B-PP
B-Cancer	325	330	tumor	tumor	NN	B-NP
O	331	342	progression	progression	NN	I-NP
O	343	352	including	include	VBG	B-PP
O	353	363	inhibition	inhibition	NN	B-NP
O	364	366	of	of	IN	B-PP
B-Cell	367	373	cancer	cancer	NN	B-NP
I-Cell	374	379	cells	cell	NNS	I-NP
O	380	389	apoptosis	apoptosis	NN	B-NP
O	390	393	and	and	CC	I-NP
O	394	405	stimulation	stimulation	NN	I-NP
O	406	408	of	of	IN	B-PP
O	409	421	angiogenesis	angiogenesis	NN	B-NP
O	421	422	.	.	.	O

O	423	427	Anti	Anti	AFX	B-NP
O	427	428	-	-	HYPH	I-NP
O	428	430	IL	IL	NN	I-NP
O	430	431	-	-	HYPH	I-NP
O	431	432	6	6	CD	I-NP
O	433	440	therapy	therapy	NN	I-NP
O	441	443	is	be	VBZ	B-VP
O	444	445	a	a	DT	B-NP
O	446	449	new	new	JJ	I-NP
O	450	458	strategy	strategy	NN	I-NP
O	459	461	in	in	IN	B-PP
O	462	465	the	the	DT	B-NP
O	466	478	inflammatory	inflammatory	JJ	I-NP
O	479	489	autoimmune	autoimmune	JJ	I-NP
O	490	498	diseases	disease	NNS	I-NP
O	499	502	and	and	CC	O
B-Cancer	503	509	cancer	cancer	NN	B-NP
O	509	510	.	.	.	O

O	511	519	Clinical	Clinical	JJ	B-NP
O	520	527	studies	study	NNS	I-NP
O	528	532	have	have	VBP	B-VP
O	533	538	shown	show	VBN	I-VP
O	539	547	elevated	elevated	JJ	B-NP
B-Organism_substance	548	553	serum	serum	NN	I-NP
O	554	556	IL	IL	NN	I-NP
O	556	557	-	-	HYPH	O
O	557	558	6	6	CD	B-NP
O	559	573	concentrations	concentration	NNS	I-NP
O	574	576	in	in	IN	B-PP
O	577	585	patients	patient	NNS	B-NP
O	586	590	with	with	IN	B-PP
B-Cancer	591	602	endometrial	endometrial	JJ	B-NP
I-Cancer	603	609	cancer	cancer	NN	I-NP
O	609	610	,	,	,	O
B-Cancer	611	614	non	non	AFX	B-NP
I-Cancer	614	615	-	-	HYPH	B-VP
I-Cancer	615	620	small	small	JJ	B-NP
I-Cancer	621	625	cell	cell	NN	I-NP
I-Cancer	626	630	lung	lung	NN	I-NP
I-Cancer	631	640	carcinoma	carcinoma	NN	I-NP
O	640	641	,	,	,	O
B-Cancer	642	652	colorectal	colorectal	JJ	B-NP
I-Cancer	653	659	cancer	cancer	NN	I-NP
O	659	660	,	,	,	O
B-Cancer	661	666	renal	renal	JJ	B-NP
I-Cancer	667	671	cell	cell	NN	I-NP
I-Cancer	672	681	carcinoma	carcinoma	NN	I-NP
O	681	682	,	,	,	O
B-Cancer	683	689	breast	breast	NN	B-NP
O	690	693	and	and	CC	O
B-Cancer	694	701	ovarian	ovarian	JJ	B-NP
I-Cancer	702	708	cancer	cancer	NN	I-NP
O	708	709	.	.	.	O

B-Organism_substance	710	715	Serum	Serum	NN	B-NP
O	716	718	IL	IL	NN	I-NP
O	718	719	-	-	HYPH	B-NP
O	719	720	6	6	CD	I-NP
O	721	727	levels	level	NNS	I-NP
O	728	737	correlate	correlate	VBP	B-VP
O	738	742	with	with	IN	B-PP
B-Cancer	743	748	tumor	tumor	NN	B-NP
O	749	754	stage	stage	NN	I-NP
O	754	755	,	,	,	O
O	756	759	and	and	CC	O
O	760	768	survival	survival	NN	B-NP
O	769	771	of	of	IN	B-PP
O	772	780	patients	patient	NNS	B-NP
O	780	781	.	.	.	O

O	782	784	In	In	IN	B-PP
O	785	789	this	this	DT	B-NP
O	790	797	article	article	NN	I-NP
O	798	800	we	we	PRP	B-NP
O	801	805	have	have	VBP	B-VP
O	806	813	focused	focus	VBN	I-VP
O	814	816	on	on	IN	B-PP
O	817	818	a	a	DT	B-NP
O	819	823	role	role	NN	I-NP
O	824	826	of	of	IN	B-PP
O	827	829	IL	IL	NN	B-NP
O	829	830	-	-	HYPH	B-NP
O	830	831	6	6	CD	I-NP
O	832	834	as	as	IN	B-PP
O	835	836	a	a	DT	B-NP
O	837	847	prognostic	prognostic	JJ	I-NP
O	848	854	factor	factor	NN	I-NP
O	855	857	in	in	IN	B-PP
O	858	865	several	several	JJ	B-NP
B-Cancer	866	878	malignancies	malignancy	NNS	I-NP
O	879	883	such	such	JJ	B-PP
O	884	886	as	as	IN	I-PP
B-Cancer	887	897	colorectal	colorectal	JJ	B-NP
I-Cancer	898	904	cancer	cancer	NN	I-NP
O	904	905	,	,	,	O
B-Cancer	906	912	breast	breast	NN	B-NP
I-Cancer	913	919	cancer	cancer	NN	I-NP
O	919	920	,	,	,	O
B-Cancer	921	928	gastric	gastric	JJ	B-NP
I-Cancer	929	935	cancer	cancer	NN	I-NP
O	936	939	and	and	CC	O
B-Cancer	940	950	pancreatic	pancreatic	JJ	B-NP
I-Cancer	951	957	cancer	cancer	NN	I-NP
O	957	958	.	.	.	O

